Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
- Sponsor
- University of Campinas, Brazil
- Study ID
- NCT02718950
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide 3.0 mg — DRUGSubjects will use liraglutide 3.0 mg for 2 weeks
Study Details
The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.
Key Dates
- Start date
- Jun 30, 2016
- Status verified
- Mar 2016
- Primary completion
- Mar 31, 2017
- Completion
- Apr 30, 2017
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Liraglutide 3.0 mgSubjects will use liraglutide 3.0 mg for 2 weeks.
Primary Outcome Measure
Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans [ Time Frame: 2 weeks ]
Central Contacts
- Bruno Geloneze, MD, PhD+55 19 35218589
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia